Dow Agro acquires Colorado seed company
Grand Valley Hybrids has been growing and conditioning hybrid seed corn in the West since 1946.
Bioscience
Articles
Local economic espionage case full of intrigue
The government's allegations read like a spy novel: Dr. Ke-xue "John" Huang lands a job at Indianapolis-based Dow AgroSciences and over five years works himself into a position of trust, with access to trade secrets and processes the company has invested $300 million to develop.
Ex-Dow Agro scientist’s espionage indictment unsealed
A federal indictment unsealed Tuesday in Indianapolis charged 45-year-old Ke-xue "John" Huang
with theft and attempted
theft of trade secrets to benefit a foreign government.
Ex-Dow AgroSciences employee accused of stealing trade secrets
The U.S. Department of Justice has charged Ke-xue Huang, a native of China’s Hunan province, of stealing trade secrets of
a Dow AgroSciences insecticide and giving them to the People’s Republic of China. Federal agents arrested the former Dow Agro
scientist July 13 in Westboro, Mass.
Indiana life sciences companies capture more venture capital money in first half of 2010
Venture dollars for Hoosier companies are still few, but the flow of deals is picking up.
AIT Labs moving headquarters, adding 160 jobs
The Indianapolis-based forensics, clinical and pharmaceutical testing firm, led by CEO Michael Evans, plans to invest $74
million to acquire and equip
an existing 90,000-square-foot building in Woodland Corporate Park near West 79th Street and Interstate 465.
Medical device startup FlowCo enlists Guidant alums
The upstart developer of a device to help doctors choose the right-sized stent to prop open clog-prone arteries has brought
aboard former Guidant Corp. executives, including Bill McConnell. Their regulatory and marketing expertise could help FlowCo Inc. bring its artery-measurement
product to market as soon as 2011.
Indiana companies that serve pharmaceutical industry grew in 2009
The firms continued to grow over the last year but face increasing challenges, according to a new report by Indianapolis-based
life sciences trade group BioCrossroads.
Builder looks to cold storage for steady work in a weak economy
Cold storage might become a hot business for a building contractor.
Lilly Endowment funds OrthoWorx effort with $7 million
A new group expected to develop the orthopedic implants industry in Warsaw will be able to proceed now that Indianapolis-based
Lilly Endowment Inc. is putting $7 million behind it, according to an announcement this morning.
Medical device developer receives $1M in federal funding
Indianapolis-based FAST Diagnostics, a developer of a method to quickly measure kidney function, announced today that it has
received $1 million in federal funding.
Abatement approval paves way for Covance jobs
The Hancock County Council this morning unanimously approved a tax-incentive agreement that should lead Covance Inc. to add
315 jobs at its Greenfield Laboratories.
Emerging life sciences companies grabbing more in government grants
More emerging life science companies have found life in the form of federal
Small Business Innovation Research grants.
Lilly cancels trials for experimental MS drug
Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis
after the drug failed to delay progression of the disease in trial patients.
Dow Agrosciences introduces genetically modified corn seed
Even after a string of acquisitions, Dow AgroSciences is a bit player in the seed business. But the new genetically
modified corn it developed with St. Louis-based giant Monsanto Co. finally provides the breakthrough product that could grow
its seed sales substantially.
Stem cell discovery promises health care revolution
Scientists are using a new stem-cell technique that may someday revolutionize care for disorders as diverse as diabetes, Alzheimer’s
disease and muscular dystrophy.
Indiana playing trailblazing role in drive to tailor pharmaceuticals to genetic makeup of individuals
Indiana is becoming not only a hotbed of “pharmacogenomics” research, but also a trailblazer in finding practical ways to
use it on the practitioner level.
Executives make many trips to Washington to argue for 14 years of sales exclusivity for new drugs made from cells
Eli Lilly & Co. executives are making many trips to Washington to argue for 14 years of sales exclusivity for new drugs made
from cells.
Biotech push may help offset generic competition; some analysts skeptical
Lilly executives want to make biotech their top focus.
Report sees jackpot with BioCrossroads, but expert sees obstacles
Three months after launching an initiative to boost drug-development firms in Indiana, officials at BioCrossroads have written
a report that attempts to show in detail the vast market opportunity they see.